In the wake of the increase in Current Liabilities in the fourth quarter 2022, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 616 other companies have achieved higher Quick Ratio than Nanomix in fourth quarter 2022. While Quick Ratio total ranking in the fourth quarter 2022 has deteriorated compared to the prior quarter from 4945 to 5705.

Explain Quick Ratio?
How much Cash & cash equivalents NNMX�s has?
What are NNMX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NNMX Quick Ratio	(Dec 31 2022) Q4	(Sep 30 2022) Q3	(Jun 30 2022) Q2	(Mar 31 2022) Q1	(Dec 31 2021) Q4
Y / Y Current Liabilities Change	21.79 %	4.91 %	-10.03 %	24.15 %	-95.03 %
Y / Y Cash & cash equivalent Change	-94.25 %	-97.92 %	-99.79 %	-76.66 %	3917.17 %
Quick Ratio MRQ	0	0.01	0	0	0.09
NNMX's Total Ranking	# 5705	# 4945	# 5754	# 5735	# 4661
Seq. Current Liabilities Change	3.93 %	-2.45 %	5.52 %	13.84 %	-10.48 %
Seq. Cash & cash equivalent Change	-65.58 %	485.48 %	-22.54 %	-96.31 %	-87.53 %

Quick Ratio fourth quarter 2022 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 617
Healthcare Sector	# 1241
Overall Market	# 5705

Quick Ratio Statistics
High	Average	Low
7.99	0.52	0
(Mar 31 2014)		(Dec 31 2020)

Financial Statements
Nanomix's Current Liabilities	$ 4 Millions	Visit NNMX's Balance sheet
Nanomix's Cash & cash equivalent	$ 0 Millions	Visit NNMX's Balance sheet
Source of NNMX's Sales		Visit NNMX's Sales by Geography

Cumulative Nanomix's Quick Ratio

NNMX's Quick Ratio for the trailling 12 Months

NNMX Quick Ratio	(Dec 31 2022) 12 Months	(Sep 30 2022) 12 Months	(Jun 30 2022) 12 Months	(Mar 31 2022) 12 Months	(Dec 31 2021) 12 Months
Y / Y Current Liabilities TTM Growth	8.25 %	-80.8 %	-82.1 %	-82.35 %	-84.08 %
Y / Y Cash & cash equivalent TTM Growth	-98.71 %	-94.27 %	-34.65 %	2792.64 %	2744.61 %
Quick Ratio TTM	0.01	0.02	0.18	0.44	0.46
Total Ranking TTM	# 4907	# 4927	# 4883	# 3004	# 3099
Seq. Current Liabilities TTM Growth	4.83 %	1.23 %	-2.92 %	5.07 %	-81.4 %
Seq. Cash & cash equivalent TTM Growth	-76.46 %	-86.43 %	-59.4 %	-0.54 %	4.53 %

Quick ratio ranking by company, industry and sector >> Back to NNMX Financial Strength Comparisons >> Go to Compare NNMX Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q4 2022 to $4.05 millions, cumulative Quick Ratio decreased to 0.01 below the Nanomix Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 602 other companies have achieved higher Quick Ratio than Nanomix. While Quick Ratio overall ranking has improved so far to 4907, from total ranking during the twelve months ending third quarter 2022 at 4927.

Explain Quick Ratio?
How much Cash & cash equivalents NNMX�s has?
What are NNMX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 603
Healthcare Sector	# 1219
Within the Market	# 4907

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.46	0.12	0
(Dec 31 2021)		(Dec 31 2019)

Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2022 MRQ Cash & cash equivalent	Dec 31 2022 MRQ Current Liabilities
American Bio Medica Corporation	0.01	$ 0.034 Millions	$ 3.602 Millions
Sangui Biotech International Inc	0.01	$ 0.009 Millions	$ 0.991 Millions
Cnbx Pharmaceuticals Inc	0.01	$ 0.022 Millions	$ 2.584 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.241 Millions	$ 29.526 Millions
Gri Bio Inc	0.01	$ 0.009 Millions	$ 1.135 Millions
Globestar Therapeutics Corporation	0.01	$ 0.008 Millions	$ 1.248 Millions
Q Biomed inc	0.01	$ 0.050 Millions	$ 8.133 Millions
Regen Biopharma Inc	0.01	$ 0.051 Millions	$ 8.595 Millions
Novaccess Global Inc	0.01	$ 0.039 Millions	$ 7.085 Millions
Cadrenal Therapeutics Inc	0.01	$ 0.033 Millions	$ 6.246 Millions
Nanomix Corp	0.00	$ 0.017 Millions	$ 4.050 Millions
Telomir Pharmaceuticals Inc	0.00	$ 0.001 Millions	$ 0.404 Millions
Lucy Scientific Discovery Inc	0.00	$ 0.026 Millions	$ 8.767 Millions
Provectus Biopharmaceuticals Inc	0.00	$ 0.022 Millions	$ 8.192 Millions
REGENEREX PHARMA, INC.	0.00	$ 0.001 Millions	$ 0.625 Millions
Kaya Holdings Inc	0.00	$ 0.018 Millions	$ 11.379 Millions
Adhera Therapeutics Inc	0.00	$ 0.032 Millions	$ 22.265 Millions
Propanc Biopharma Inc	0.00	$ 0.004 Millions	$ 3.063 Millions
Rebus Holdings Inc	0.00	$ 0.005 Millions	$ 5.242 Millions
Altamira Therapeutics Ltd	0.00	$ 0.017 Millions	$ 19.188 Millions

Date modified: 2026-09-08T15:10:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.